NASDAQ:CNTB Connect Biopharma (CNTB) Stock Price, News & Analysis $2.06 +0.30 (+17.05%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.16 +0.10 (+4.90%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Connect Biopharma Stock (NASDAQ:CNTB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Connect Biopharma alerts:Sign Up Key Stats Today's Range$1.78▼$2.0650-Day Range$0.95▼$2.3852-Week Range$0.51▼$2.86Volume194,143 shsAverage Volume131,232 shsMarket Capitalization$114.78 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingStrong Buy Company Overview Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California. Read More Connect Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreCNTB MarketRank™: Connect Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 360th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingConnect Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageConnect Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Connect Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Connect Biopharma are expected to decrease in the coming year, from ($0.22) to ($0.32) per share.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Connect Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.08% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently decreased by 43.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.08% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently decreased by 43.91%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.49 News SentimentConnect Biopharma has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.13 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Connect Biopharma this week, compared to 1 article on an average week.Search Interest4 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Connect Biopharma's insider trading history. Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTB Stock News HeadlinesConnect Biopharma to Present at Two Upcoming Investor Conferences in SeptemberAugust 27, 2025 | globenewswire.comWe're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn RateAugust 26, 2025 | finance.yahoo.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer. | Timothy Sykes (Ad)Connect Biopharma (NASDAQ:CNTB) Raised to Hold at Wall Street ZenAugust 24, 2025 | americanbankingnews.comConnect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program NationwideAugust 14, 2025 | globenewswire.comConnect Biopharma Posts Q2 Revenue DropAugust 13, 2025 | theglobeandmail.comConnect Biopharma sees cash runway into 2027August 13, 2025 | msn.comConnect Biopharma reports Q2 EPS (23c) vs. 27c last yearAugust 13, 2025 | msn.comSee More Headlines CNTB Stock Analysis - Frequently Asked Questions How have CNTB shares performed this year? Connect Biopharma's stock was trading at $1.38 on January 1st, 2025. Since then, CNTB shares have increased by 49.3% and is now trading at $2.06. How were Connect Biopharma's earnings last quarter? Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) released its quarterly earnings results on Thursday, May, 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. When did Connect Biopharma IPO? Connect Biopharma (CNTB) raised $150 million in an IPO on Friday, March 19th 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO. Who are Connect Biopharma's major shareholders? Top institutional shareholders of Connect Biopharma include BML Capital Management LLC (3.28%), AlphaCore Capital LLC (0.14%), Koa Wealth Management LLC (0.09%) and XTX Topco Ltd (0.05%). How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Connect Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings5/15/2025Today9/01/2025Next Earnings (Estimated)9/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTB CIK1835268 Webwww.connectbiopharm.com Phone18587271045Fax+1 8586147007Employees110Year FoundedN/APrice Target and Rating Average Price Target for Connect Biopharma$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+239.8%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio7.24 Quick Ratio7.24 Sales & Book Value Annual Sales$26.03 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book1.23Miscellaneous Outstanding Shares55,720,000Free Float43,129,000Market Cap$114.78 million OptionableOptionable Beta-0.09 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CNTB) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredSell this, buy thatI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.